



# MITTAL AGARWAL & COMPANY

## CHARTERED ACCOUNTANTS

Limited Review Report on the Standalone Unaudited Quarterly Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended

Review Report to  
The Board of Directors  
Gufic Biosciences Limited

- 1) We have reviewed the accompanying statement of Standalone Unaudited Financial Results of Gufic Biosciences Limited (the "Company") for the quarter ended 30 June 2025 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2) This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit, and accordingly, we do not express an audit opinion.
- 4) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Mittal Agarwal & Company  
Chartered Accountants  
(Firm Registration No. 131025W)



*Deepesh Mittal*

Deepesh Mittal  
Partner

Membership No. 539486

Place: Mumbai  
Dated: 13/08/2025  
UDIN: 25039486BMKSKP3140



Limited Review Report on the Consolidated Unaudited Quarterly Financial Results of the Company Pursuant to Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended

Review Report to  
The Board of Directors  
Gufic Biosciences Limited

- 1) We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of **Gufic Biosciences Limited** and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2025 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
- 2) This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3) We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4) We also performed procedures in accordance with the Circular No. CIR/CFD/CMDI/44/20 19 dated March 29, 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.
- 5) The Statement includes the result of the entities:

Name of the Entity	Relationship
Gufic UK Limited	Wholly Owned Foreign Subsidiary
Veira Life FZE	Wholly Owned Foreign Subsidiary
Gufic Prime Private Limited	Subsidiary





# MITTAL AGARWAL & COMPANY

CHARTERED ACCOUNTANTS

- 6) The financial results of wholly owned foreign subsidiaries have been prepared in accordance with the accounting principles generally accepted in their respective countries and audited under the applicable generally accepted auditing standards of those countries. The management of the Company has converted the financial results of such wholly owned foreign subsidiaries from their local accounting principles to Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013. Our conclusion, insofar as it relates to the balances and affairs of these subsidiaries located outside India, is based on the financial results/statements as certified by the management and the conversion adjustments prepared by them.

Our conclusion is not modified in respect of this matter.

- 7) Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Mittal Agarwal & Company  
Chartered Accountants  
(Firm Registration No. 131025W)



*Deepesh Mittal*

**Deepesh Mittal**  
Partner

Membership No. 539486

Place: Mumbai  
Dated: 13/08/2025  
UDIN: 25539486BMKSK82529

## GUFIC BIOSCIENCES LIMITED

Regd. Office : 37, Kamala Bhavan II, S. Nityanand Road, Andheri (East), Mumbai - 400069  
(CIN- L24100MH1984PLC033519)

Website - www.gufic.com, email - corporaterelations@guficbio.com, Ph-022 67261000, Fax - 022 67261068

(Rs. in Lakhs except EPS)

### Unaudited Standalone and Consolidated Statement of Financial Results for the Quarter Ended June 30, 2025

1]	Sr. No.	Particulars	Standalone				Consolidated				
			Quarter Ended		Year ended		Quarter Ended		Year ended		
			30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25	30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25	
			Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	Unaudited	Audited	
	1	<b>Income</b>									
	a	Revenue from operations	22,691.15	20,502.01	20,281.20	81,980.60	22,372.25	20,502.01	20,281.20	81,980.60	
	b	Other income	89.42	38.30	125.46	361.50	92.52	39.45	125.46	362.65	
		<b>Total Income</b>	<b>22,780.57</b>	<b>20,540.31</b>	<b>20,406.66</b>	<b>82,342.10</b>	<b>22,464.77</b>	<b>20,541.46</b>	<b>20,406.66</b>	<b>82,343.25</b>	
	2	<b>Expenses</b>									
	a	Cost of materials consumed	8,851.58	12,291.24	7,276.68	34,420.10	8,851.58	12,291.24	7,276.68	34,420.10	
	b	Purchase of stock-in-trade	1,426.82	1,084.89	1,244.60	5,541.43	1,426.82	1,084.89	1,244.60	5,541.43	
	c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	252.16	(4,409.37)	952.61	(2,491.42)	(201.27)	(4,409.37)	952.61	(2,491.42)	
	d	Employee benefits expense	3,599.68	3,557.45	2,904.63	12,718.64	3,599.68	3,557.45	2,904.63	12,718.64	
	e	Finance cost	923.36	839.98	462.41	2,451.90	923.36	839.98	462.41	2,451.90	
	f	Depreciation and amortisation expense	771.89	784.33	430.51	2,106.44	771.89	784.33	430.51	2,106.46	
	g	Other expenses	5,327.38	5,313.86	4,324.49	18,152.26	5,365.30	5,340.45	4,324.75	18,181.79	
		<b>Total Expenses</b>	<b>21,152.87</b>	<b>19,462.38</b>	<b>17,595.94</b>	<b>72,899.35</b>	<b>20,737.36</b>	<b>19,488.97</b>	<b>17,596.20</b>	<b>72,928.90</b>	
	3	Total Profit before exceptional items and tax (1-2)	1,627.70	1,077.93	2,810.72	9,442.75	1,727.41	1,052.49	2,810.46	9,414.35	
	4	Exceptional items	-	-	-	-	-	-	-	-	
	5	<b>Total Profit Before Tax</b>	<b>1,627.70</b>	<b>1,077.93</b>	<b>2,810.72</b>	<b>9,442.75</b>	<b>1,727.41</b>	<b>1,052.49</b>	<b>2,810.46</b>	<b>9,414.35</b>	
	6	<b>Tax expense</b>									
		Current tax	222.00	27.00	700.00	1,872.00	222.00	27.00	700.00	1,872.00	
		Deferred tax	198.37	251.18	24.89	575.13	198.37	251.20	24.86	575.13	
		Short/(Excess) tax provision of earlier years	-	2.34	-	2.34	-	2.34	-	2.34	
		<b>Total Tax Expenses</b>	<b>420.37</b>	<b>280.52</b>	<b>724.89</b>	<b>2,449.47</b>	<b>420.37</b>	<b>280.54</b>	<b>724.86</b>	<b>2,449.47</b>	
	7	<b>Net Profit for the period from continuing operations</b>	<b>1,207.33</b>	<b>797.41</b>	<b>2,085.83</b>	<b>6,993.28</b>	<b>1,307.04</b>	<b>771.95</b>	<b>2,085.60</b>	<b>6,964.88</b>	
		Less: Share of Profit / (Loss) transferred to Minority Interest	-	-	-	-	-	-	(0.01)	(0.08)	
	8	<b>Total Profit for period</b>	<b>1,207.33</b>	<b>797.41</b>	<b>2,085.83</b>	<b>6,993.28</b>	<b>1,307.04</b>	<b>771.95</b>	<b>2,085.61</b>	<b>6,964.96</b>	
	9	<b>Other Comprehensive Income (OCI)</b>									
		Items that will not be reclassified to Profit or Loss	-	(17.06)	-	(17.06)	-	(17.06)	-	(17.06)	
		Less: Income tax relating to items that will not be reclassified to Profit or Loss	-	4.29	-	4.29	-	4.29	-	4.29	
		Other Comprehensive Income / Loss (net of taxes)	-	(12.77)	-	(12.77)	-	(12.77)	-	(12.77)	
	10	<b>Total Comprehensive Income</b>	<b>1,207.33</b>	<b>784.64</b>	<b>2,085.83</b>	<b>6,980.51</b>	<b>1,307.04</b>	<b>759.18</b>	<b>2,085.61</b>	<b>6,952.19</b>	
	11	<b>Other Equity Reserves</b>				59,133.51				59,104.90	
	12	<b>Details of Equity Share Capital</b>									
		Paid-up equity share capital	1,002.78	1,002.78	1,002.78	1,002.78	1,002.78	1,002.78	1,002.78	1,002.78	
		Face value of equity share capital (Rs.)	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	
	13	<b>Earning per equity share</b>									
	i	Basic earnings per share from continuing and discontinued operations	1.20	0.80	2.08	6.97	1.30	0.77	2.08	6.95	
	ii	Diluted earnings per share from continuing and discontinued operations	1.20	0.80	2.08	6.97	1.30	0.77	2.08	6.95	




*only for identification purpose*

## 2] Notes:

1. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of Companies Act, 2013, read with rules issued thereunder.
2. The above results for the quarter ended June 30, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on August 13, 2025. The Statutory Auditors have carried out limited review of the results for quarter ended June 30, 2025.
3. The Company's business activity falls within a single operating segment i.e. Pharmaceuticals.
4. The Consolidated Financial Results for the quarter and financial year ended June 30, 2025, have been prepared by the Company considering the financials of its wholly owned subsidiaries, Gufic UK Limited and Veira Life FZE, and its subsidiary, Gufic Prime Private Limited. As of June 30, 2025, the Company has not made any investment in Gufic Ireland Limited ("GIL"), incorporated in 2023 with the intention of becoming a wholly owned subsidiary, nor has GIL commenced its business operations; hence, consolidation of its accounts with those of the Company was not required.
5. The equity shares and basic/diluted earnings per share has been presented in accordance with Ind AS - 33-Earning per share.
6. The figures for the quarter ended March 31, 2025 are balancing figures between audited figures in respect of the full financial year and the unaudited published year-to-date figures up to the third quarter ended December 31, 2024 which were subjected to limited review.
7. Previous year/quarters figures have been regrouped/reclassified, wherever necessary.

FOR GUFIC BIOSCIENCES LIMITED

  
PRANAV J. CHOKSI  
CEO & WHOLE TIME DIRECTOR  
DIN : 00001731

PLACE : MUMBAI  
DATE : 13/08/2025



*only for identification purpose*